Mycobacterium Tuberculosis Treatment Market

Mycobacterium Tuberculosis Treatment Market Outlook (2022-2032)

Worldwide revenue from the mycobacterium tuberculosis treatment market was US$ 1.97 Bn in 2021, with the global market estimated to expand at a CAGR of 1.2% to reach US$ 2.40 Bn by the end of 2032.

As assessed by Persistence Market Research, mycobacterium tuberculosis treatment for active tuberculosis (TB) accounted for a market value of US$ 1.35 Bn in 2021. Overall, mycobacterium tuberculosis drug sales accounted for approximately 2.7% revenue share of the global infectious disease treatment market in 2021.

The global market for mycobacterium tuberculosis treatment recorded a historic CAGR of 9.5% in the last 9 years from 2012 to 2021.

• According to WHO, 1.6 million persons worldwide died from tuberculosis (TB) in 2021. Following COVID-19 and HIV/AIDS, TB is the second infectious killer in the world and the 13th-largest cause of death overall. Globally, 10.6 million cases of tuberculosis (TB) were reported in 2021, which included around 6 million males, approximately 3.4 million females, and more than 1 million children.
• In March 2021, the World Health Organization published data in a journal titled "Impact of the COVID-19 pandemic on TB diagnosis and mortality in 2020," which revealed that 1.4 million fewer people than in 2019 received TB treatment in 2020, a 21% decline from 2019.
• Additionally, as per an article published by the International Journal of Tuberculosis and Lung Disease in June 2021 titled "The impact of COVID-19 on TB: a review of the data”, it was noted that the provision of tuberculosis services has been hampered by a high TB burden due to inadequate equipment and capacity, restrictions on migration (affecting supplies, and healthcare staff), and resource reallocation.

Despite the negative impact of COVID-19 on the overall market, it is set to exhibit growth over the coming years. Also, due to factors such as governments’ challenges and the National Strategic Plan to eradicate tuberculosis by 2025, the market is likely to show steady growth over the coming years.

How are Mycobacterium Tuberculosis Drug Manufacturers Growing?

“Rising Incidence of Multi-Drug Resistant Tuberculosis (MDR-TB)”

Over the projected period, the prevalence of multi-drug resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR) is anticipated to increase in developing nations. Since there are few marketable effective pharmacological alternatives, low patient adherence to medicine continues to be an issue in the development of MDR TB.

Through programs run by the WHO, such as Directly Observed Therapy (DOT), this wave of antimicrobial drug resistance in mycobacterium TB strains has inspired a global initiative. Additionally, the development of shorter treatment regimens to combat drug resistance through cooperation between international organizations such as Unitaid, WHO, UNICEF, and TB Alliance is addressing unmet medical requirements, which is anticipated to drive market expansion.

“Advancements for Improvement of Novel Therapeutics and International Funding”

Advanced technology and the improvement of novel therapeutics are anticipated to shorten the time of remedy for tuberculosis and the occurrence of tuberculosis. Moreover, despite existing medicines for tuberculosis, there is a constant demand for novel therapeutics, especially in lower economies, for multidrug-resistant tuberculosis and pediatric tuberculosis. In low- and middle-income countries, international donor funding remains critical. The chief source is the Global Fund to fight tuberculosis and increase awareness among the population.

How is Market Progress Being Affected to Some Extent?

“Generic Drugs - Competition for Market Players”

MDR-TB is a type of tuberculosis caused by bacteria that are resistant to rifampicin and isoniazid, the two most potent first-line TB medications. Second-line medications can be used to treat and even eradicate MDR-TB. However, second-line treatment choices are few and require lengthy chemotherapy using expensive and hazardous drugs.

There is a wide range of low-cost prescription options as a result of the availability of generic alternatives to the medications used to treat tuberculosis. Additionally, many drugs are currently in pipeline, which is expected to increase the competition among manufacturers in the near future.

Certain pharmaceutical manufacturers will face generic competition as patented branded pharmaceuticals lose their patent protection. This means that companies designing and manufacturing original products (drug molecules) will face more competition. Patients and doctors may choose to use generic medications because they are less expensive than brand-name drugs. As a result, issues with patent expiration will impede the market for mycobacterium tuberculosis treatment to some extent.

Country-wise Insights

Why is the U.S. Mycobacterium Tuberculosis Treatment Market Booming?

“Government Funding Programs for Tuberculosis”

The U.S. accounted for 12.3% share of the global market in 2021, and a similar trend is expected over the forecast period.

The incidence of tuberculosis among U.S.-born persons increased from 0.71 in 2020 to 0.79 in 2021 (cases per 100, 000 population), whereas, in non-U.S.-born persons, it increased from 11.71 to 12.61 (cases per 100, 000 population) in 2021, thereby increasing the incidence of tuberculosis, which is a major driver for market growth in the country.

• According to WHO, the United States (US) Government is the largest contributor of funding to the Global Fund and also the largest bilateral donor; overall, it contributes close to 50% of international donor funding for TB.

Why is China Emerging as a Prominent Market for Mycobacterium Tuberculosis Drug Suppliers?

“Rising Burden of Latent Tuberculosis Infection”

China held the largest market share of 58.8% of the East Asia mycobacterium tuberculosis treatment market in 2021, with a market value of US$ 280.9 Mn.

• According to CDC China, China was predicted to have the highest worldwide burden of latent tuberculosis infection (LTBI), with around 350 million infections that are at risk for active TB illness.
• In July 2019, the State Council of China released the Healthy China Initiative 2019–2030, which included 15 special campaigns, including the Tuberculosis Control Action to guide the way for China’s TB prevention and control.

As such, the increasing burden of latent TB and government initiatives are expected to drive market growth in China over the forecast period

Will India be a Lucrative Market for Mycobacterium Tuberculosis Treatment?

“High Prevalence of Tuberculosis and Increasing Digital Initiatives”

India held 45.2% share of the South Asian market in 2021.

• According to an article published in the Journal of Family Medicine and Primary Care in January 2022, titled "Status of drug-resistant tuberculosis among patients attending a tuberculosis unit of West Bengal", it was noted that the prevalence of tuberculosis and multidrug-resistant tuberculosis (MDR-TB) is the highest in India, which is first in the global ranking of detecting new cases each year.
• Additionally, according to WHO, India's anticipated incidence of tuberculosis in 2021 was 2.14 million, 18% higher than in 2020.
• Recently, in March 2022, Johnson & Johnson launched a digital initiative #BeTheChangeForTB, a collaborative effort of the Central TB Division, the Indian Ministry of Health and Family Welfare, and the United States Agency for International Development (USAID), supporting the objective of the Indian Government to eradicate tuberculosis.

Category-wise Insights

Which Disease Type is driving Global Market Growth?

“Rising Incidence of Active TB”

Active TB held 68.5% share of the overall disease type segment within the global market. The active TB (ATB) segment dominated the market due to the growing incidence of MDR TB cases, which can be considered incomplete treatment patterns in high-risk and low- and middle-income countries.

• According to the Centers for Disease Control and Prevention (CDC), globally, most people suffer from active TB as compared to latent TB.

Which Treatment Type is in High Demand?

“Standard Treatment Regimen- 1st Line of Drugs”

The first line of drugs held the largest market share of 74.5% in 2021. The first line of drugs is a standard treatment pattern for tuberculosis patients. Increasing adoption of novel therapeutics as combination therapies is expected to boost the first line of drug treatment types in the market.

Competitive Landscape

Key players in the mycobacterium tuberculosis treatment industry are engaged in activities such as new product launches, acquisitions, collaborations, and expansion for the advancement and development of new products and therapies.

For instance,

• In August 2022, Janssen Pharmaceutica NV, Otsuka Pharmaceutical Co., Ltd. Evotec, GSK, and the Bill & Melinda Gates Foundation collaborated with the Project to Accelerate New Treatments for Tuberculosis (PAN-TB) for combination treatment regimens into phase 2 clinical development.
• In September 2021, Lupin Limited received a non-exclusive license grant from nonprofit drug developer, TB Alliance to manufacture the anti-TB drug pretomanid and commercialized it in 140 countries, especially in the highest TB burden countries around the world.

Mycobacterium Tuberculosis Treatment Industry Report Scope

Key Segments of Mycobacterium Tuberculosis Treatment Industry Research

By Disease Type:

• Latent TB
• Active TB

By Treatment Type:

• First-Line of Drugs
• Second-Line of Drugs

By Route of Administration:

• Oral
• Intravenous
• Intramuscular

By Distribution Channel:

• Hospital Pharmacies
• Online Pharmacies
• Retail Pharmacies
• Institutional and Retail Sales

By Region:

• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East & Africa

To know more about delivery timeline for this report Contact Sales